| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-10-0646 |
| P698 | PubMed publication ID | 20551065 |
| P50 | author | Gideon Bollag | Q61518938 |
| Kathryn Packman | Q131140131 | ||
| Kenneth Kolinsky | Q131140135 | ||
| P2093 | author name string | Hong Yang | |
| Richard Lee | |||
| Fei Su | |||
| Brian Higgins | |||
| David Heimbrook | |||
| Joseph F Grippo | |||
| Raman Iyer | |||
| Sylvia Zhao | |||
| Stanley Kolis | |||
| Kathleen Schostack | |||
| Mary Ellen Simcox | |||
| Zenaida Go | |||
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5518-5527 | |
| P577 | publication date | 2010-06-15 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models | |
| P478 | volume | 70 |
| Q35600821 | A MEK-independent role for CRAF in mitosis and tumor progression |
| Q36971266 | A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice |
| Q37510470 | A PGC1α-mediated transcriptional axis suppresses melanoma metastasis |
| Q54478395 | A combined 3D-QSAR and molecular docking strategy to understand the binding mechanism of (V600E)B-RAF inhibitors. |
| Q36764374 | A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma |
| Q37815139 | A new era: melanoma genetics and therapeutics |
| Q35233178 | A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition |
| Q37651094 | Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor |
| Q36152396 | Aberrant expression of COT is related to recurrence of papillary thyroid cancer |
| Q37727061 | Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma |
| Q39119920 | Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. |
| Q36251418 | Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models |
| Q42279549 | Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. |
| Q37182194 | Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. |
| Q38007036 | Advances in cutaneous melanoma |
| Q39068444 | Altered mRNA expression related to the apoptotic effect of three xanthones on human melanoma SK-MEL-28 cell line. |
| Q39788891 | Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma |
| Q39401378 | Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma |
| Q27851696 | Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer |
| Q37247862 | Antitumor Activity of a Humanized, Bivalent Immunotoxin Targeting Fn14-Positive Solid Tumors |
| Q52312711 | Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. |
| Q38771627 | BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma |
| Q38498046 | BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma |
| Q38114763 | BRAF in Melanoma: Current Strategies and Future Directions |
| Q58712577 | BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1 |
| Q28076667 | BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy |
| Q38077556 | BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. |
| Q28543370 | BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications |
| Q27851843 | BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors |
| Q44549974 | BRAFmutations in chronic lymphocytic leukemia |
| Q38917480 | Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients |
| Q37851738 | Biological challenges of BRAF inhibitor therapy |
| Q55474327 | Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses. |
| Q39399366 | CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity |
| Q35583851 | CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity |
| Q38268502 | Catalytic mechanisms and regulation of protein kinases |
| Q52655309 | Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations |
| Q35023498 | Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations |
| Q96428151 | Clinical Development of BRAF plus MEK Inhibitor Combinations |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q24597152 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma |
| Q37146673 | Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer |
| Q37693426 | Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation |
| Q35007886 | Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium |
| Q37990653 | Co-development of a companion diagnostic for targeted cancer therapy |
| Q38777596 | Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma |
| Q84712443 | Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors |
| Q34469532 | Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing |
| Q34551705 | Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib |
| Q41874659 | Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations |
| Q36392912 | Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients |
| Q34149419 | Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish |
| Q38940098 | Converting biology into clinical benefit: lessons learned from BRAF inhibitors |
| Q35749307 | Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma |
| Q30456779 | Cutaneous side effects of vemurafenib: a case report and discussion |
| Q39212238 | Dabrafenib for the treatment of melanoma |
| Q27851801 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. |
| Q89823393 | Degradation of proteins by PROTACs and other strategies |
| Q38086762 | Dermatological adverse events from BRAF inhibitors: a growing problem. |
| Q27644273 | Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors |
| Q38731016 | Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells. |
| Q63213728 | Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations |
| Q27853105 | Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib |
| Q36058758 | Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. |
| Q33888789 | Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts |
| Q36189476 | Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization |
| Q34773994 | Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. |
| Q33988809 | Differential Inhibitor Sensitivity between Human Kinases VRK1 and VRK2 |
| Q27685316 | Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives |
| Q34653547 | Drug safety evaluation of vemurafenib in the treatment of melanoma. |
| Q37038401 | Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. |
| Q35841043 | EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib |
| Q52684307 | ERK5 is activated by oncogenic BRAF and promotes melanoma growth |
| Q34547540 | Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations |
| Q46584676 | Efficient in vivo microRNA targeting of liver metastasis |
| Q38145387 | Emerging BRAF inhibitors for melanoma. |
| Q60051005 | Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma |
| Q36864736 | Evolving approaches to patients with advanced differentiated thyroid cancer |
| Q37974926 | Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics |
| Q37607913 | Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation. |
| Q46528844 | Fe-SOD cooperates with Nutlin3 to selectively inhibit cancer cells in vitro and in vivo |
| Q34422021 | Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity |
| Q28533949 | From bench to bedside: lessons learned in translating preclinical studies in cancer drug development |
| Q28484649 | Functional profiling of live melanoma samples using a novel automated platform |
| Q43127268 | Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". |
| Q42919827 | Genetic Testing for Lung Cancer: Reflex Versus Clinical Selection |
| Q36563659 | Genetics of melanoma |
| Q84987341 | Going beyond EGFR |
| Q36750123 | Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in Melanoma |
| Q39412894 | Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. |
| Q46836891 | Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas |
| Q38333942 | Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation |
| Q39324719 | Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models. |
| Q37054958 | Immunotherapy in the management of melanoma: current status |
| Q38756848 | Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. |
| Q39022580 | In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database |
| Q60912960 | Induced cross-resistance of BRAF melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment |
| Q51483259 | Insight into the structural features of pyrazolopyrimidine- and pyrazolopyridine-based B-Raf(V600E) kinase inhibitors by computational explorations |
| Q59793078 | Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology |
| Q33709769 | Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways |
| Q37815135 | KRAS and BRAF: drug targets and predictive biomarkers |
| Q28829200 | Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies |
| Q37381163 | Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression |
| Q36415602 | Low-grade serous carcinomas of the ovary contain very few point mutations |
| Q33566681 | MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor |
| Q53168966 | Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma |
| Q38033744 | Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies |
| Q34059350 | MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1 |
| Q38821729 | Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance |
| Q85509862 | Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma |
| Q38203956 | Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer |
| Q35177372 | Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma |
| Q38384301 | Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma |
| Q34660901 | Multikinase inhibitors use in differentiated thyroid carcinoma. |
| Q37705228 | Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. |
| Q54324284 | Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma |
| Q27025345 | Mutation of the BRAF genes in non-small cell lung cancer |
| Q39714436 | Mutations driving CLL and their evolution in progression and relapse |
| Q38185477 | Neoadjuvant treatment of melanoma: case reports and review |
| Q47688064 | New perspectives for targeting RAF kinase in human cancer. |
| Q38050461 | New therapeutical strategies in the treatment of metastatic disease. |
| Q35052935 | No increase in IgG4-positive plasma cells in limbal Rosai-Dorfman disease |
| Q28265862 | Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics |
| Q96953882 | Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations |
| Q35914464 | Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF |
| Q37886864 | Overcoming metastatic melanoma with BRAF inhibitors |
| Q33688428 | PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation |
| Q54603099 | PLX4032 and melanoma: resistance, expectations and uncertainty |
| Q39640222 | PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas |
| Q28076200 | Pharmacogenetics and pharmacogenomics as tools in cancer therapy |
| Q38978336 | Polysaccharides from Tricholoma matsutake and Lentinus edodes enhance 5-fluorouracil-mediated H22 cell growth inhibition |
| Q37593264 | Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway |
| Q53412605 | Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma |
| Q27853295 | Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade |
| Q54301896 | Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes |
| Q50068807 | RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. |
| Q90596702 | RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling |
| Q37048053 | RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors |
| Q34488278 | Rapid, Microwave-Assisted Organic Synthesis of Selective (V600E)BRAF Inhibitors for Preclinical Cancer Research |
| Q33646519 | Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target |
| Q38459448 | Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation. |
| Q36836677 | Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. |
| Q27023596 | Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options |
| Q39421033 | Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation |
| Q33946905 | Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis |
| Q39428029 | Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition |
| Q91781720 | Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy |
| Q39844384 | Role of the protein kinase BRAF in the pathogenesis of endometriosis. |
| Q28730438 | Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials |
| Q27276774 | Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study |
| Q38114116 | Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2 |
| Q38585847 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. |
| Q52657766 | Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy. |
| Q58615651 | Stress and interferon signalling-mediated apoptosis contributes to pleiotropic anticancer responses induced by targeting NGLY1 |
| Q24594790 | Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib |
| Q37625891 | Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. |
| Q58574814 | Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells |
| Q38553161 | Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. |
| Q26865490 | Systemic and targeted therapies for early-stage lung cancer |
| Q39196241 | TSC1 involvement in bladder cancer: diverse effects and therapeutic implications |
| Q28083446 | Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK |
| Q38041723 | Targeted Therapy for Brain Metastases |
| Q34222257 | Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma |
| Q34158153 | Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor |
| Q34540273 | Targeted therapy for melanoma: a primer |
| Q42172884 | Targeted therapy; from advanced melanoma to the adjuvant setting |
| Q37859164 | Targeting BRAF in advanced melanoma: a first step toward manageable disease |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q38124821 | Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma |
| Q35859282 | Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies |
| Q82213660 | Targeting mutant BRAF in metastatic melanoma |
| Q37859008 | Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q38191794 | Targeting tumour-supportive cellular machineries in anticancer drug development |
| Q37308167 | The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells |
| Q39515657 | The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells |
| Q41891513 | The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies |
| Q38741062 | The IKKα-dependent non-canonical pathway of NF-κB activation is constitutively active and modulates progression-related functions in a subset of human melanomas |
| Q37997546 | The Role of the PI3K-AKT Pathway in Melanoma |
| Q34316552 | The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma |
| Q35878248 | The current state of targeted therapy in melanoma: this time it's personal |
| Q38559739 | The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma |
| Q39803993 | The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations |
| Q35121301 | The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells |
| Q42262009 | Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma |
| Q37632230 | Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications |
| Q38716887 | Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. |
| Q37951743 | Towards new therapeutic approaches for malignant melanoma |
| Q40092107 | Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. |
| Q38082713 | Update on the Targeted Therapy of Melanoma |
| Q35682567 | Variations of BRAF mutant allele percentage in melanomas |
| Q37949571 | Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma |
| Q38014531 | Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. |
| Q39687000 | Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma |
| Q38118851 | Vemurafenib and ipilimumab: New agents for metastatic melanoma |
| Q38101603 | Vemurafenib in melanoma |
| Q34641609 | Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma |
| Q38040456 | Vemurafenib: in unresectable or metastatic melanoma |
| Q38056972 | Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies |
| Q28276886 | Vemurafenib: the first drug approved for BRAF-mutant cancer |
| Q39723484 | Virus Reactivation: a Panoramic View in Human Infections |
| Q52753134 | mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors |
Search more.